Satellite Symposia

Satellite symposia are non-commercial, grant funded learning activities that are planned and conducted by the corporate community in conjunction with Nexus 2021. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.

Registration, content, and continuing education is the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.

For more information, please contact us.

All times are listed in Mountain Time (MT).

Monday, Oct. 18 | 4:30–6pm

  • Provided by Creative Educational Concepts.
  • Supported by American Regent.
  • Continuing education credit available for pharmacists and physicians.
  • Contact hours: 1.5

Program Description

Activity attendees will be given the opportunity to interact with world-renowned expert faculty across all clinically relevant aspects of iron deficiency anemia (IDA) management in chronic kidney disease (CKD). The session will begin with a thorough review of iron metabolism and absorption principles, including the practical distinctions between absolute and functional iron deficiency, and the impact of that distinction on treatment. An exhaustive appraisal of the multifactorial etiologies and foundational pathophysiology of anemia in CKD will follow, with a central emphasis on the role of hepcidin in a hyperinflammatory disease state like CKD and how that process should lead to preferential use of intravenous (IV) iron versus oral iron modalities in these patients.

Learning Objectives:

  • Understand the multifactorial etiologies and complex pathophysiology of iron deficiency anemia (IDA) in chronic kidney disease (CKD), and evaluate the role of inflammation and hepcidin on iron supplementation strategies.
  • Appraise completed, ongoing, and planned clinical trials of IV iron therapies for IDA management in CKD, and identify how the innovative nanoparticle design of next-generation IV iron products dramatically improves upon the safety profiles of high-molecular weight (HMW) dextran agents, with anaphylaxis rates as low as 0.1%.
  • Using a real-world case-based format, interpolate the expanding scientific knowledge base regarding the impact of inflammation and hepcidin on iron availability and utilization, especially in a hyperinflammatory state like CKD, and the resultant rationale for preferential treatment with IV iron vs. oral iron.

Program Manager:
Ashley Lilly 
Creative Educational Concepts, LLC
alilly@ceconcepts.com

Registration:
https://www.ceconcepts.com/content/namcp#group-tabs-node-course-default5

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by an educational grant from Janssen Biotech Inc.
  • Continuing education credit available for managed care and oncology pharmacists.
  • Contact hours: 1.5

Program Description

Monoclonal antibodies are approved for use in treating both newly diagnosed and relapsed/refractory multiple myeloma, with numerous combinations of therapy recommended in national guidelines. Therapy selection includes past treatments, candidacy for stem cell transplant, and other patient-specific factors. This activity will review the clinical data for incorporating monoclonal antibodies into the treatment paradigm of multiple myeloma. Additionally, the economic impact of monoclonal antibody therapy will be discussed, with an emphasis on strategies managed care pharmacists can implement to assist with formulary development.

Learning Objectives:

  • Examine recent FDA approvals and clinical trials incorporating monoclonal antibodies for multiple myeloma.
  • Analyze clinical guidelines for monoclonal antibody use in newly diagnosed and relapsed/refractory multiple myeloma.
  • Integrate multiple myeloma treatment outcomes with economic considerations to develop formulary management strategies.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

Monday, Oct. 18 | 7–8:30pm

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by an educational grant from Global Blood Therapeutics.
  • Continuing education credit available for pharmacists, managed care professionals.
  • Contact hours: 1.5

Program Description

Patients with sickle cell disease (SCD) experience increased rates of emergency department visits and hospitalizations due to vaso-occlusive events. Patients experience chronic and episodic pain but acute pain crises due to vaso-occlusion can affect multiple organ systems and may result in increased disability or early mortality and reduced quality of life. While increased newborn and prenatal screening for SCD has improved the life expectancy, optimal management of this lifelong illness is multifaceted and requires a patient-centered approach. Pharmacists and managed care professionals can have significant impact in providing quality care by facilitating access to treatment and helping overcome treatment challenges. New and emerging pharmacologic therapies present potential benefits for patients with SCD, and managed care professionals need to be prepared to incorporate these newer agents into the treatment landscape for SCD.

Learning Objectives:

  • Document the pathophysiology of sickle cell disease and the treatment challenges associated with the management of the disease and its comorbidities.
  • Differentiate the various pharmacotherapeutic options and treatment strategies for SCD including recent clinical and real-world data.
  • Explain the health-related quality of life and economic burden of SCD and evaluate the various therapies for appropriate utilization.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

  • Provided by PRIME Education.
  • This activity is supported by an educational grant from Bristol Myers Squibb.
  • Continuing education credit available for pharmacists, physicians, physician assistants, nurse practitioners, and nurses.
  • Contact hours: 1.25

Program Description

Hypertrophic cardiomyopathy (HCM) is currently managed through symptomatic treatment or surgical intervention. Join leading managed care and HCM experts as they discuss the latest clinical data on emerging therapies and applications for managed care decision-making to optimize outcomes for patients with this devastating disease.

Don't miss this opportunity to:

  • Hear about new clinical data on emerging therapies in HCM.
  • Learn about applications of new evidence on managed care decision-making for patients with HCM.
  • Engage in live Q&A with renowned experts in HCM.

This can't-miss live session is designed to provide extensive face-to-face interactive learning, peer discussion, and dedicated time for Q&A.

Learning Objectives:

  • Summarize recent clinical findings on pathophysiological mechanisms that underlie disease progression in hypertrophic cardiomyopathy (HCM).
  • Differentiate the utility of therapies for HCM based on mechanisms of action and clinical data on efficacy and safety.
  • Align decision-making with current evidence, treatment guidelines, and patient factors to ensure appropriate patient selection and prompt access to HCM therapies.

Program Manager:
Jill Friedman
PRIME Education
j.friedman@primeinc.org

Registration:
https://primeinc.org/17LV213?utm_source=AMCP&utm_medium=webtxt&utm_id=17LV213

Tuesday, Oct. 19 | 6:30–8am

  • Provided by AMCP. 
  • Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals. 
  • Continuing education credit available for pharmacists. 
  • Contact hours: 1.5 

Program Description

Atopic dermatitis, often incorrectly referred to as eczema, is an inflammatory skin disorder most commonly presenting during early childhood and affecting individuals through adulthood. Disease burden on the health care system is estimated to exceed $4.3 billion annually with urgent care costs doubling in recent years. The recurrent nature of intense itching and eczematous lesions along with increased risk for other diseases of atopy can lead to a significant burden on quality of life. Advances in identifying the genetic and immunologic components of atopic dermatitis is fueling an expansive growth of novel treatment approaches. This will result in improved disease burden with increased utilization and costs.   

During this session, faculty will discuss the complications atopic dermatitis has on quality of life at various ages, treatment strategies to minimize disease burden, the health care utilization and costs involved with the management of atopic dermatitis, and explore emerging agents that improve outcomes in different age groups with atopic dermatitis.

Learning Objectives:

  • Define the etiology and clinical presentation of atopic dermatitis.  
  • Describe the influence atopic dermatitis has on quality of life both mentally and physically for children, adolescents, adults, and their caregivers. 
  • Recognize the impact atopic dermatitis has on health care utilization and prescription drug costs within managed care organizations. 
  • Discuss current and pipeline treatment options for different age groups with atopic dermatitis. 

Registration (Live Session):
https://amcp.formstack.com/forms/nexus2021_satellitesymposium_regform

Registration (Livestream):
Registration link to come.

Tuesday, Oct. 19 | 7–8:30pm

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by an educational grant from Bristol Myers Squibb.
  • Continuing education credit available for pharmacists, managed care professionals.
  • Contact hours: 1.5

Program Description

Multiple sclerosis (MS) is a lifelong, progressive disease and the leading cause of nontraumatic disability in young adults. The unpredictable course of disease creates a substantial impact on quality of life for those living with MS and significant economic burden to the healthcare system when patients experience relapses or progression. Unfortunately, MS is incurable; however, there are several disease-modifying treatments (DMTs) that can alter progression of this incapacitating illness. Recent approvals have added to the armamentarium of available agents, and careful selection is necessary to ensure optimal patient outcomes. Managed care professionals and pharmacists must be able to assess new and emerging treatments and incorporate them into value-based care models. This discussion will center on clinical data for agents under investigation for treatment of MS as well as managed care considerations for facilitating access to medications as they become available. Expert panelists will also review strategies to mitigate costs of disease progression and disability in patients with MS.

Learning Objectives:

  • Break down the current treatment challenges and unmet needs in managing multiple sclerosis (MS) and the burden on patients and the healthcare system.
  • Interpret the most current guideline recommendations, evidence-based data, and new and emerging treatment strategies to address unmet needs in MS care.
  • Examine the healthcare utilization and costs associated with MS and the managed care considerations in facilitating access to efficacious and individualized treatment.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by an educational grant from Genentech, a member of the Roche Group.
  • Continuing education credit available for pharmacists, managed care professionals.
  • Contact hours: 1.5

Program Description

Diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) are serious ophthalmic conditions caused by destabilization of the mature vasculature due to the synergistic action of growth factors angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A. Both conditions ultimately lead to visual impairment, inflammation, and leaking, which conveys significant burdens for patients. Current treatments inhibit only VEGF-A; however, treatments that target both growth factors have proven more effective in reducing inflammation and leakage and stabilizing blood vessels than those that only target one. Managed care professionals should stay up-to-date on new therapeutic targets and longer-lasting formulations currently under investigation. These therapies have the potential to diminish the frequency required for eye injections, which can improve patient adherence and decrease adverse effects. This activity will review the benefits and challenges associated with emerging DME and nAMD therapies. Managed care professionals must consider the efficacy and safety data associated with early interventions and continued access to these therapies to improve adherence and lower costs for patients with DME and

Learning Objectives:

  • Examine the burden of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and challenges associated with current treatment options.
  • Explore novel agents in nAMD/DME treatment including mechanisms of action, and efficacy and safety data.
  • Identify barriers in optimizing treatment in nAMD and DME and opportunities for managed care professionals to collaborate with providers to improve care.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

Wednesday, Oct. 20 | 6:30–8am

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by educational grants from AstraZeneca and Daiichi Sankyo.
  • Continuing education credit available for managed care pharmacists.
  • Contact hours: 1.5

Program Description

The advent of additional HER2-targeted therapies to the armamentarium of breast cancer therapies has contributed to improved outcomes for patients with HER2-positive disease. To provide access to cost-effective treatment for patients, managed care professionals need to be familiar with the clinical data and indications for use of these agents in HER2-positive disease. This activity will delve into nuances among available and emerging agents as well as how these agents fit within guideline recommendations and affect formulary decisions. The expert faculty will also present strategies managed care professionals can use to develop and evaluate evidence-based oncology clinical pathways to positively impact quality of care while managing costs and factors affecting medication utilization, especially in patients receiving HER2-targeted therapies.

Learning Objectives:

  • Distinguish HER2-targeted treatment and differences among therapies.
  • Analyze current guidelines and emerging options for HER2-positive breast cancer.
  • Employ oncology clinical pathways as a tool to assist in access and resource utilization for HER2-positive breast cancer.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

  • Provided by Medscape. 
  • Supported by an Independent Educational Grant from Takeda Pharmaceuticals U.S.A. Inc.; Developed through the strategic partnership between the Academy of Managed Care Pharmacy (AMCP) and Medscape.  
  • Continuing education credit available for pharmacists attending AMCP Nexus 2021 and physician meeting attendees.
  • Contact hours: 1.5  

Program Description 

The overall goal of this activity is to improve understanding of the evidence of targeted therapies for IBD as well as evaluating the value of different therapies on the overall management of a patient.  

Learning Objectives: 

Upon completion of this activity, learners will demonstrate increased knowledge regarding: 

  • Clinical utility of PARP inhibitors in the management of advanced OC. 
  • Managed care considerations to facilitate optimal use of PARP inhibitors in advanced OC. 
  • The role of the managed care pharmacist in the care of patients with advanced OC.

And greater confidence in their ability to:  

  • Collaborate with the other members of OC treatment team to provide patient-centered care in advanced disease  

Program Manager:
Kristen Gresham 
Medscape 
kgresham@medscapelive.com 

Registration: 
www.medscape.org/symposium/ibd-managed-care 

Wednesday, Oct. 20 | 7–8:30pm

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by an educational grant from Coherus BioSciences.
  • Continuing education credit available for managed care and oncology pharmacists.
  • Contact hours: 1.5

Program Description

The cost of cancer care greatly impacts the US healthcare system from a financial perspective. Biologic agents have shown efficacy in the treatment of many malignancies; however, they are associated with a high cost. The use of biosimilar agents in the oncology setting has the potential for cost savings and improved access to care. This program will review available oncology biosimilars, potential benefits and challenges in use, and will also emphasize payer strategies to help assist with access to care and prescriber acceptance into clinical practice.

Learning Objectives:

  • Analyze economic benefits of biosimilar use in oncology care.
  • Investigate challenges of biosimilar uptake in clinical practice and considerations to reduce barriers to formulary and pathway inclusion.
  • Explore payer strategies to manage the use of biosimilars in oncology care and improve patient access.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

  • Provided by Medscape Oncology. 
  • Supported by AstraZeneca Pharmaceuticals, LP, GlaxoSmithKline, and Merck & Co. Inc. 
  • Continuing education credit available for this activity is intended for managed care pharmacists and clinical pharmacists, including those practicing in oncology.  
  • Contact hours: 1.5  

Program Description 

In the past few years, PARP inhibitors have emerged as an effective new approach to the challenges posed by ovarian cancer. This 90-minute symposium will explore some of the nuances associated with PARP inhibitors, including which patients are eligible for treatment and in which disease setting they should be used. It will also focus on enhancing strategies for a successful collaboration between pharmacists of different disciplines and between pharmacists and other healthcare providers to improve the care and outcomes for patients with advanced OC treated with PARP inhibitors.  

Learning Objectives: 

Upon completion of this activity, learners will demonstrate increased knowledge regarding: 

  • Clinical utility of PARP inhibitors in the management of advanced OC. 
  • Managed care considerations to facilitate optimal use of PARP inhibitors in advanced OC. 
  • The role of the managed care pharmacist in the care of patients with advanced OC. 

Greater confidence in their ability to:

  • Collaborate with the other members of OC treatment team to provide patient-centered care in advanced disease.  

Program Manager:
Kristen Gresham 
Medscape 
kgresham@medscapelive.com 

Registration: 
www.medscape.org/symposium/ovarian-cancer 

Thursday, Oct. 21 | 6:30–8am

  • Provided by Pharmacy Times Continuing Education™. 
  • This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.
  • Continuing education credit available for managed care pharmacists. 
  • Contact hours: 1.5  

Program Description

In recent decades, significant progress has been made in the management of diabetes with novel medications, insulin formulations, and use of technology. However, people with diabetes continue to experience long-term microvascular complications, such as retinopathy and nephropathy. Nephropathy occurs in more than 40% of people with diabetes and is the leading cause of chronic kidney disease (CKD) worldwide; therefore, prevention and optimal management of CKD in diabetes remains a key treatment target. Pharmacists need to be familiar with screening parameters for the early identification and treatment of CKD in patients with diabetes because aggressive management of comorbidities and complications may prevent progression to end-stage renal disease. Optimal management has the potential for cost savings, as progression of CKD and cardiovascular events lead to increased healthcare resource utilization and remain a leading driver of costs for patients with diabetes. The expert panelists will discuss the current landscape of CKD prevention and management including renal protective strategies and emerging treatments.

Learning Objectives:

  • Explain the epidemiology of diabetes and chronic kidney disease (CKD) and the pathology of kidney disease in this population, along with the drivers of CKD progression. 
  • Interpret the current clinical guidelines and data for CKD in type 2 diabetes along with medication recommendations and emerging treatment options aimed at addressing the gaps in care. 
  • Examine the economic and clinical burden of diabetic CKD and opportunities for managed care interventions to improve costs and patient outcomes. 

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021

  • Provided by Pharmacy Times Continuing Education™.
  • This activity is supported by an educational grant from Bristol Myers Squibb.
  • Continuing education credit available for managed care pharmacists.
  • Contact hours: 1.5

Program Description

The use of chimeric antigen receptor-modified (CAR) T-cell therapies is becoming widespread in the treatment of hematologic malignancies. CAR T-cell therapies are associated with unique care considerations including management of adverse effects and coordination of treatment plans with the multidisciplinary team. This activity will focus on approved CAR T-cell therapies as well as guideline recommendations for place in the treatment paradigm. Additionally, expert panelists will discuss factors impacting access to care, with an emphasis on how to integrate CAR T-cell therapies into clinical practice.

Learning Objectives:

  • Explore clinical trial data for approved indications for chimeric antigen receptor-modified (CAR) T-cell therapies and their impact in cancer care.
  • Interpret guideline recommendations for implementation of CAR T-cell therapy in treatment pathways and management of associated adverse effects.
  • Examine payment mechanisms and associated therapy-specific factors to optimize the use of CAR T-cell therapy and improve access for patients.

Program Manager:
Liz Rauh
Pharmacy Times Continuing Education™
lrauh@pharmacytimes.com

Registration:
https://event.pharmacytimes.org/nexus2021